Athersys (NASDAQ:ATHX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHXFree Report) in a report issued on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

Shares of NASDAQ ATHX opened at $0.00 on Friday. Athersys has a 12-month low of $0.01 and a 12-month high of $1.99. The company has a market capitalization of $277,735.50, a PE ratio of 0.00 and a beta of -0.90. The firm’s 50-day moving average is $0.01 and its two-hundred day moving average is $0.03.

About Athersys

(Get Free Report)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Further Reading

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.